UM  > 健康科學學院
Non-classical estrogen signaling in ovarian cancer improves chemo-sensitivity and patients outcome
Dapeng Hao1; Jingjing Li1; Jianlin Wang1; Yuan Meng1; Zhiqiang Zhao1; Chao Zhang1; Kai Miao1; Chuxia Deng1; Benjamin K. Tsang3; Li Wang1,2; Li-jun Di1
2019-05-31
Source PublicationTHERANOSTICS
ISSN1838-7640
Volume9Issue:13Pages:3952-3965
Abstract

Deficiency in homologous recombination repair (HRR) is frequently associated with hormone-responsive cancers, especially the epithelial ovarian cancer (EOC) which shows defects of HRR in up to half of cases. However, whether there are molecular connections between estrogen signaling and HRR deficiency in EOC remains unknown.

Methods: We analyzed the estrogen receptor α (ERα) binding profile in EOC cell lines and investigated its association with genome instability, HRR deficiency and sensitivity to chemotherapy using extensive public datasets and in vitro/in vivo experiments.

Results: We found an inverse correlation between estrogen signaling and HRR activity in EOC, and the genome-wide collaboration between ERα and the co-repressor CtBP. Though the non-classical AP-1-mediated ERα signaling, their targets were highly enriched by HRR genes. We found that depleting ERα in EOC cells up-regulates HRR activity and HRR gene expression. Consequently, estrogen signaling enhances the sensitivity of ovarian cancer cells to chemotherapy agents in vitro and in vivo. Large-scale analyses further indicate that estrogen replacement and ESR1 expression are associated with chemo-sensitivity and the favorable survival of EOC patients.

Conclusion: These findings characterize a novel role of ERα in mediating the molecular connection between hormone and HRR in EOC and encourage hormone replacement therapy for EOC patients.

KeywordOvarian Cancer Estrogen Signaling Deficiency Of Homologous-recombination Chemotherapy Hormone Replacement
DOI10.7150/thno.30814
Indexed BySCI
Language英语
WOS Research AreaResearch & Experimental Medicine
WOS SubjectMedicine, Research & Experimental
WOS IDWOS:000469954200019
PublisherIVYSPRING INT PUBL, PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionFaculty of Health Sciences
Corresponding AuthorLi Wang; Li-jun Di
Affiliation1.Cancer Center, Faculty of health Sciences, University of Macau, Macau, SAR of the People’s Republic of China
2.Metabolism Core, Faculty of Health Sciences, University of Macau, Macau, SAR of the People’s Republic of China
3.Department of Obstetrics and Gynecology and Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada
First Author AffilicationFaculty of Health Sciences
Corresponding Author AffilicationFaculty of Health Sciences
Recommended Citation
GB/T 7714
Dapeng Hao,Jingjing Li,Jianlin Wang,et al. Non-classical estrogen signaling in ovarian cancer improves chemo-sensitivity and patients outcome[J]. THERANOSTICS,2019,9(13):3952-3965.
APA Dapeng Hao.,Jingjing Li.,Jianlin Wang.,Yuan Meng.,Zhiqiang Zhao.,...&Li-jun Di.(2019).Non-classical estrogen signaling in ovarian cancer improves chemo-sensitivity and patients outcome.THERANOSTICS,9(13),3952-3965.
MLA Dapeng Hao,et al."Non-classical estrogen signaling in ovarian cancer improves chemo-sensitivity and patients outcome".THERANOSTICS 9.13(2019):3952-3965.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Dapeng Hao]'s Articles
[Jingjing Li]'s Articles
[Jianlin Wang]'s Articles
Baidu academic
Similar articles in Baidu academic
[Dapeng Hao]'s Articles
[Jingjing Li]'s Articles
[Jianlin Wang]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Dapeng Hao]'s Articles
[Jingjing Li]'s Articles
[Jianlin Wang]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.